Summit Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Summit Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||
| current assets: | ||||||||||||||||||||
| cash and cash equivalents | 297,872,000 | 211,526,000 | 104,862,000 | 93,775,000 | 28,434,000 | 61,294,000 | 71,425,000 | 23,792,000 | 42,116,000 | 70,969,000 | 348,607,000 | 121,971,000 | 103,386,000 | 102,194,000 | 66,417,000 | 21,270,000 | ||||
| restricted cash | 319,000 | 318,000 | 325,000 | 323,000 | 320,000 | 317,000 | 300,000,000 | |||||||||||||
| short-term investments | 149,789,000 | 307,487,000 | 393,122,000 | 297,035,000 | 95,386,000 | 114,817,000 | 175,153,000 | 172,898,000 | 170,963,000 | |||||||||||
| prepaid expenses and other current assets | 11,049,000 | 9,118,000 | 10,519,000 | 2,410,000 | 2,052,000 | 5,323,000 | ||||||||||||||
| total current assets | 309,240,000 | 370,751,000 | 423,750,000 | 490,290,000 | 328,794,000 | 163,265,000 | 189,712,000 | 204,951,000 | 227,501,000 | 248,027,000 | 656,712,000 | 137,119,000 | 79,398,000 | 99,435,000 | 97,312,000 | 102,210,000 | 121,482,000 | 125,217,000 | 87,674,000 | 42,077,000 |
| non-current assets: | ||||||||||||||||||||
| property and equipment | 690,000 | 652,000 | 254,000 | 265,000 | 223,000 | 181,000 | 204,000 | 229,000 | 225,000 | 412,000 | 906,000 | 930,000 | 1,095,000 | 965,000 | 694,000 | 656,000 | 757,000 | 684,000 | 725,000 | |
| operating lease right-of-use assets | 5,552,000 | 6,351,000 | 7,144,000 | |||||||||||||||||
| goodwill | 2,039,000 | 1,923,000 | 1,864,000 | 1,991,000 | 1,880,000 | 1,875,000 | 1,893,000 | 1,814,000 | 1,883,000 | 1,839,000 | 1,798,000 | 1,655,000 | 1,806,000 | 1,953,000 | 2,009,000 | 2,001,000 | 2,057,000 | 2,047,000 | 2,030,000 | 2,335,000 |
| other assets | 6,516,000 | 4,145,000 | 1,850,000 | 1,863,000 | 1,879,000 | 1,875,000 | 4,322,000 | 4,332,000 | 254,000 | 156,000 | 577,000 | 140,000 | 179,000 | 166,000 | 170,000 | |||||
| total assets | 324,037,000 | 383,822,000 | 435,560,000 | 502,852,000 | 341,856,000 | 176,781,000 | 202,949,000 | 218,476,000 | 237,372,000 | 254,897,000 | 664,168,000 | 155,327,000 | 95,718,000 | 116,472,000 | 113,374,000 | 128,673,000 | 145,517,000 | 140,794,000 | 102,498,000 | 56,865,000 |
| liabilities and stockholders' equity | ||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||
| accounts payable | 22,982,000 | 4,994,000 | 4,636,000 | 3,252,000 | 3,340,000 | 6,371,000 | 2,667,000 | 3,314,000 | 987,000 | 710,000 | 355,000 | 1,431,000 | 3,574,000 | 6,959,000 | 4,374,000 | 5,875,000 | 6,949,000 | 4,114,000 | 6,140,000 | 2,493,000 |
| accrued liabilities | 26,148,000 | 21,185,000 | 19,554,000 | 18,477,000 | 12,457,000 | 6,547,000 | 8,783,000 | 10,664,000 | 7,197,000 | 4,261,000 | ||||||||||
| accrued compensation | 6,592,000 | 4,396,000 | 11,977,000 | 7,961,000 | 4,877,000 | 6,033,000 | 5,429,000 | 3,510,000 | 3,529,000 | 2,416,000 | 5,641,000 | 2,509,000 | 1,906,000 | 1,514,000 | 4,125,000 | |||||
| operating lease liabilities, current portion | 3,118,000 | 3,543,000 | 3,765,000 | |||||||||||||||||
| other current liabilities | 1,485,000 | 759,000 | 1,797,000 | 1,027,000 | 806,000 | 788,000 | 717,000 | 484,000 | 619,000 | 320,000 | 662,000 | 209,000 | 265,000 | 678,000 | 897,000 | 1,030,000 | 661,000 | 581,000 | 729,000 | 354,000 |
| total current liabilities | 60,325,000 | 34,877,000 | 41,729,000 | 59,009,000 | 140,168,000 | 23,438,000 | 20,405,000 | 113,742,000 | 11,931,000 | 17,443,000 | 38,782,000 | 16,682,000 | 15,173,000 | 22,724,000 | 25,623,000 | 22,789,000 | 21,888,000 | 73,052,000 | 19,890,000 | 14,742,000 |
| non-current liabilities: | ||||||||||||||||||||
| operating lease liabilities, net of current portion | 2,435,000 | 2,907,000 | 3,453,000 | |||||||||||||||||
| other non-current liabilities | 1,838,000 | 1,708,000 | 1,630,000 | 1,716,000 | 1,596,000 | 3,310,000 | 1,562,000 | 1,476,000 | 1,511,000 | 1,481,000 | 1,429,000 | 2,424,000 | 2,594,000 | 2,751,000 | 2,776,000 | 2,690,000 | 2,689,000 | 2,603,000 | 2,511,000 | 2,277,000 |
| total liabilities | 64,598,000 | 39,492,000 | 46,812,000 | 64,932,000 | 146,781,000 | 132,571,000 | 125,257,000 | 119,097,000 | 117,773,000 | 121,415,000 | 537,514,000 | 22,079,000 | 44,401,000 | 52,065,000 | 30,090,000 | 26,375,000 | 26,090,000 | 76,389,000 | 23,045,000 | 20,004,000 |
| commitments and contingencies | ||||||||||||||||||||
| stockholders' equity: | ||||||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at june 30, 2025 and december 31, 2024, respectively | ||||||||||||||||||||
| common stock | 7,428,000 | 7,416,000 | 7,376,000 | 7,371,000 | 7,243,000 | 7,020,000 | 7,017,000 | 6,978,000 | 6,976,000 | 6,976,000 | 2,110,000 | 2,013,000 | 981,000 | 981,000 | 980,000 | 976,000 | 974,000 | 829,000 | 826,000 | 672,000 |
| additional paid-in capital | 2,097,957,000 | 1,616,963,000 | 1,598,230,000 | 1,586,227,000 | 1,287,447,000 | 1,076,370,000 | 1,066,381,000 | 1,051,415,000 | 1,050,483,000 | 1,048,608,000 | 504,767,000 | 493,553,000 | 391,220,000 | 388,328,000 | 384,049,000 | 377,213,000 | 373,882,000 | 295,129,000 | 293,367,000 | 242,395,000 |
| accumulated other comprehensive loss | -2,752,000 | -2,563,000 | -2,285,000 | -2,308,000 | -2,499,000 | -2,449,000 | -2,448,000 | -2,323,000 | -2,437,000 | -1,396,000 | -1,893,000 | -3,217,000 | -3,168,000 | -3,957,000 | -2,197,000 | -3,442,000 | -2,579,000 | -3,119,000 | -3,794,000 | -7,032,000 |
| accumulated deficit | -1,843,194,000 | -1,277,486,000 | -1,214,573,000 | -1,153,370,000 | -1,097,116,000 | -1,036,731,000 | -993,258,000 | -956,691,000 | -935,423,000 | -920,706,000 | -378,330,000 | -359,101,000 | -337,716,000 | -320,945,000 | -299,548,000 | -272,449,000 | -252,850,000 | -228,434,000 | -210,946,000 | -199,174,000 |
| total stockholders' equity | 259,439,000 | 344,330,000 | 388,748,000 | 437,920,000 | 195,075,000 | 44,210,000 | 99,379,000 | 119,599,000 | 133,482,000 | 126,654,000 | 133,248,000 | 51,317,000 | 64,407,000 | 83,284,000 | 102,298,000 | 119,427,000 | 64,405,000 | 79,453,000 | 36,861,000 | |
| total liabilities and stockholders' equity | 324,037,000 | 383,822,000 | 435,560,000 | 502,852,000 | 341,856,000 | 176,781,000 | 218,476,000 | 237,372,000 | 254,897,000 | 664,168,000 | 155,327,000 | 95,718,000 | 116,472,000 | 113,374,000 | 128,673,000 | 145,517,000 | 140,794,000 | 102,498,000 | 56,865,000 | |
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at march 31, 2025 and december 31, 2024, respectively | ||||||||||||||||||||
| research and development tax credit receivable | 557,000 | 660,000 | 953,000 | 945,000 | 848,000 | 812,000 | 4,607,000 | 4,500,000 | 5,766,000 | 12,958,000 | 14,132,000 | 15,290,000 | 15,695,000 | 10,072,000 | 9,856,000 | |||||
| liabilities and stockholders’ equity | ||||||||||||||||||||
| promissory note payable to a related party | 24,500,000 | 100,000,000 | 100,000,000 | 100,000,000 | 25,312,000 | 25,055,000 | 54,963,000 | |||||||||||||
| stockholders’ equity: | ||||||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at december 31, 2024 and 2023, respectively | ||||||||||||||||||||
| right-of-use assets | 7,976,000 | 8,716,000 | 9,373,000 | 5,859,000 | 6,403,000 | 6,996,000 | 3,928,000 | 4,175,000 | 4,230,000 | 2,017,000 | 2,432,000 | 2,790,000 | 1,884,000 | 2,212,000 | 1,487,000 | 554,000 | 628,000 | |||
| lease liabilities | 3,792,000 | 3,688,000 | 3,699,000 | 2,809,000 | 2,780,000 | 2,928,000 | 1,693,000 | 1,690,000 | 1,392,000 | 684,000 | 907,000 | 1,091,000 | 941,000 | 1,006,000 | 1,056,000 | 390,000 | 386,000 | |||
| lease liabilities, net of current portion | 4,207,000 | 5,017,000 | 5,823,000 | 3,290,000 | 3,879,000 | 4,331,000 | 2,491,000 | 2,763,000 | 2,973,000 | 1,322,000 | 1,535,000 | 1,691,000 | ||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at september 30, 2024 and december 31, 2023, respectively | ||||||||||||||||||||
| accrued acquired in-process research and development | 15,000,000 | |||||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at june 30, 2024 and december 31, 2023, respectively | ||||||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at march 31, 2024 and december 31, 2023, respectively | ||||||||||||||||||||
| accounts receivable | 349,000 | 140,000 | 238,000 | 870,000 | 1,464,000 | 2,290,000 | 1,053,000 | 447,000 | 4,080,000 | |||||||||||
| prepaid expenses | 2,441,000 | 5,074,000 | 6,093,000 | 1,186,000 | 1,504,000 | 1,622,000 | 5,393,000 | 4,350,000 | 7,161,000 | 8,409,000 | 5,727,000 | 7,995,000 | 9,547,000 | 7,141,000 | ||||||
| other current assets | 181,000 | 120,000 | 1,787,000 | 409,000 | 486,000 | 428,000 | 2,300,000 | 1,475,000 | 1,201,000 | 1,191,000 | 963,000 | 985,000 | 1,523,000 | 1,667,000 | ||||||
| promissory note payable to related parties | 19,770,000 | |||||||||||||||||||
| non-current liabilities | ||||||||||||||||||||
| promissory notes payable to related parties | 100,000,000 | 494,540,000 | ||||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at december 31, 2023 and 2022, respectively | ||||||||||||||||||||
| total stockholders’ equity | 77,692,000 | |||||||||||||||||||
| total liabilities and stockholders’ equity | 202,949,000 | |||||||||||||||||||
| accrued expenses | 3,654,000 | 3,868,000 | 12,304,000 | 11,141,000 | 5,513,000 | 7,569,000 | 7,432,000 | 6,132,000 | 4,915,000 | 4,398,000 | ||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at september 30, 2023 and december 31, 2022, respectively | ||||||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at june 30, 2023 and december 31, 2022, respectively | ||||||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at march 31, 2023 and december 31, 2022, respectively | ||||||||||||||||||||
| intangible assets | 7,952,000 | 8,900,000 | 9,866,000 | 10,399,000 | 10,608,000 | 11,161,000 | 11,359,000 | 11,515,000 | 11,101,000 | |||||||||||
| deferred revenue and other income | 3,231,000 | 5,097,000 | 7,939,000 | |||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at december 31, 2022 and 2021, respectively | ||||||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shares authorized; none issued and outstanding at september 30, 2022 and december 31, 2021, respectively | ||||||||||||||||||||
| cash | 57,335,000 | 77,450,000 | 71,791,000 | 80,248,000 | ||||||||||||||||
| preferred stock, 0.01 par value, 20,000,000 shared authorized; none issued and outstanding at june 30, 2022 and december 31, 2021, respectively | ||||||||||||||||||||
| deferred revenue and other income, net of current portion | ||||||||||||||||||||
| deferred revenue | 7,511,000 | |||||||||||||||||||
| research and development tax credit receivables | 10,353,000 | 13,596,000 | 7,919,000 | |||||||||||||||||
| deferred revenue and income | 7,140,000 | 7,423,000 | 8,370,000 | |||||||||||||||||
| accounts and other receivable | 331,000 | |||||||||||||||||||
| contingent consideration | ||||||||||||||||||||
| current assets | ||||||||||||||||||||
| property, plant and equipment | 724,000 | |||||||||||||||||||
| current liabilities | ||||||||||||||||||||
| deferred income | 7,111,000 | |||||||||||||||||||
| deferred tax liability | 2,108,000 | |||||||||||||||||||
| stockholders'equity |
We provide you with 20 years of balance sheets for Summit Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Summit Therapeutics. Explore the full financial landscape of Summit Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Summit Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.